AbbVie starts Phase 2 obesity trial of Gubra-discovered amylin analog ABBV-295

By Public Technologies
  • Gubra flagged AbbVie’s detailed Phase 1 results for obesity candidate ABBV-295, presented at EASD 2026 in Milan.
  • Data showed meaningful weight loss across dosing schedules, supporting continued development of the long-acting amylin program.
  • Tolerability looked favorable, with side effects mainly mild and concentrated early in treatment.
  • Findings supported less frequent dosing potential, strengthening differentiation from incretin-based weight-loss drugs.
  • A Phase 2 trial in adults with overweight or obesity started in August 2026 under AbbVie’s lead.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk